A clinical rating scale for progressive supranuclear palsy
- PMID: 17405767
- DOI: 10.1093/brain/awm032
A clinical rating scale for progressive supranuclear palsy
Abstract
We devised a Progressive Supranuclear Palsy (PSP) Rating Scale comprising 28 items in six categories: daily activities (by history), behaviour, bulbar, ocular motor, limb motor and gait/midline. Scores range from 0 to 100, each item graded 0-2 (six items) or 0-4 (22 items). Inter-rater reliability is good, with intra-class correlation coefficient for the overall scale of 0.86 (95% CI 0.65-0.98). A single examiner applied the PSPRS at every visit for 162 patients. Mean rate of progression was 11.3 (+/-11.0) points per year. Neither onset age nor gender correlated well with rate of progression. Median actuarially corrected survival was 7.3 years. The PSPRS score was a good independent predictor of subsequent survival (P < 0.0001). For example, for patients with scores from 40 to 49, 3-year survival was 41.9% (95% CI 31.0-56.6) but 4-year survival was only 17.9% (95% CI 10.2-31.5). For those patients, likelihood or retaining some gait function was 51.7% (40.0-66.9) at 1 year but only 6.5% (1.8-23.5) at 3 years. We conclude that the PSPRS is a practical measure that is sensitive to disease progression and could be useful as a dependent variable in observational or interventional trials and as an indicator of prognosis in clinical practice.
Comment in
-
Clinical assessment of progressive supranuclear palsy over time: new rating scale validated.Nat Clin Pract Neurol. 2007 Nov;3(11):600-1. doi: 10.1038/ncpneuro0603. Epub 2007 Aug 21. Nat Clin Pract Neurol. 2007. PMID: 17712327 No abstract available.
Similar articles
-
Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy.Mov Disord. 2010 Jun 15;25(8):1040-6. doi: 10.1002/mds.23023. Mov Disord. 2010. PMID: 20131396
-
[A clinical and epidemiological description of a series of patients diagnosed as suffering from progressive supranuclear palsy].Rev Neurol. 2004 Dec 1-15;39(11):1006-10. Rev Neurol. 2004. PMID: 15597260 Spanish.
-
[Progressive supranuclear palsy: a clinical, natural history and disability study].Rev Neurol (Paris). 2003 Jan;159(1):31-42. Rev Neurol (Paris). 2003. PMID: 12618651 Clinical Trial. French.
-
Progressive supranuclear palsy.Rev Neurol Dis. 2007 Fall;4(4):209-16. Rev Neurol Dis. 2007. PMID: 18195676 Review.
-
Progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): a short historical review.Neurologist. 2007 Sep;13(5):302-4. doi: 10.1097/01.nrl.0000254743.69160.b3. Neurologist. 2007. PMID: 17848869 Review.
Cited by
-
POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study.J Neurol. 2012 Oct;259(10):2232-3. doi: 10.1007/s00415-012-6535-1. Epub 2012 May 12. J Neurol. 2012. PMID: 22580846 No abstract available.
-
DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy.Front Neurol. 2021 May 25;12:644064. doi: 10.3389/fneur.2021.644064. eCollection 2021. Front Neurol. 2021. PMID: 34113306 Free PMC article.
-
Impact of the Anticholinergic Burden on Disease-Specific Symptoms in Parkinsonian Syndromes.Brain Sci. 2024 Aug 11;14(8):805. doi: 10.3390/brainsci14080805. Brain Sci. 2024. PMID: 39199497 Free PMC article.
-
MRI gray and white matter measures in progressive supranuclear palsy and corticobasal syndrome.J Neurol. 2016 Oct;263(10):2022-31. doi: 10.1007/s00415-016-8224-y. Epub 2016 Jul 13. J Neurol. 2016. PMID: 27411806
-
Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?Mov Disord Clin Pract. 2018 Nov 8;5(6):603-606. doi: 10.1002/mdc3.12678. eCollection 2018 Nov-Dec. Mov Disord Clin Pract. 2018. PMID: 30637280 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous